Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer.
|
15806173 |
2005 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been strongly implicated in the genesis of ovarian cancer.
|
17178867 |
2006 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results underline the prognostic significance of PIK3CA in ovarian carcinoma and argue against a simple linear model of PIK3CA gain/amplification followed by PI3K activation and consecutive AKT phosphorylation in ovarian carcinoma.
|
17377809 |
2007 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that E-cadh-mediated AJ formation contributes to PI3K/AKT activation in EOC cells by a mechanism that appears to be restricted to these cells provides the underpinning for therapeutic strategies that exploit PI3K inhibition to halt EOCs.
|
19151754 |
2009 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.
|
19240722 |
2009 |
Carcinoma, Ovarian Epithelial
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
PIK3CA amplification was seen in 54 of 152 (35.5%) EOC cases analyzed; PIK3CA gene mutations in 6/153 EOC (3.9%); KRAS mutations in 3/154 EOC (1.9%), BRAF mutations in 3/156 EOC (1.9%), p53 mutation in 50/154 EOC (32.5%), and loss of PTEN protein expression in 33/144 EOC (22.9%). p110 alpha overexpression was associated with increased phosphorylation of AKT-Ser 473 and with the proliferation marker Ki-67.
|
19638206 |
2009 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinically, COX-2 was overexpressed in 60.3% of EOC and was significantly associated with activated AKT (p < 0.0001).
|
19621391 |
2010 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
|
20661229 |
2011 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic complexity and AKT dependence in serous ovarian cancer.
|
22328975 |
2012 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Differential activity of AKT serves as the mechanistic basis for regulating MYXV-mediated oncolysis of EOC spheroids during key steps of the metastatic program.
|
22306204 |
2012 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although many tumors presented a single lesion (28/93, of which 23 overexpressed PIK3CA, 1 overexpressed AKT and 4 had lost PTEN), many OC (35/93) presented multiple alterations within the PI3K pathway.
|
23408974 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.
|
23869765 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
WAVE1 might promote the proliferative and invasive malignant behaviors through the activation of the PI3K/AKT and p38MAPK signaling pathways in EOC.
|
23680521 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on recent research on the PI3K/AKT/mTOR pathway and its role in the progression and tumorigensis of ovarian cancer.
|
23591839 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
We established that amplifications in 14q32.33 were associated with reduced OS, PFS, PFI and platinum resistance in three independent cohorts, suggesting that AKT1 amplifications act as a potentially predictive marker for EOC treated with platinum-based chemotherapy.
|
25281495 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, REDD1 and p-AKT over-expression may serve as a prognostic biomarker in OC, but KRAS mutations and REDD1 protein over-expression were not correlated in OC.
|
25337238 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, VEGF expression could reverse the effect of miR-718 on ovarian cancer by increasing the levels of phosphorylated AKT.
|
24815691 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting the PI3K/AKT pathway may be a useful treatment for ovarian carcinoma.
|
25216292 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that FAK inhibition can suppress ovarian cancer cells migration and invasion through inhibiting downstream signaling (PI3K/AKT), which might be a therapeutic target or biomarker for ovarian cancer.
|
24115647 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer.
|
25176450 |
2014 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we investigated the activation of mTOR complexes (mTORC1 and mTORC2) in a cohort of 156 EOC from Saudi Arabia by immunohistochemistry in a tissue microarray format. mTORC1 and mTORC2 were found to be activated in 55 of 146 (37.7%) and 63 of 140 (45%) of EOC samples, respectively. mTORC1 was significantly associated with mTORC2 (p < 0.0001) activation and both mTOR complexes were significantly associated with p-AKT (p = 0.0205 and 0.0298) and p-P70S6 (p < 0.0001 and 0.0035), respectively.
|
26023849 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
|
25677064 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results of the present study demonstrated that PI3K/AKT and Rab25 significantly contributed to cisplatin resistance in human epithelial ovarian cancer; in addition, silencing Rab25 or inhibiting the PI3K/AKT pathway markedly increased the sensitivity of these cells to cisplatin.
|
25405658 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these findings demonstrate that EMT can be regulated by the CCL19/CXCR7 axis in epithelial ovarian carcinomas and then involved in the tumor cell invasion and metastasis process via activation of AKT and ERK pathways.
|
25359618 |
2015 |
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas.
|
25307974 |
2015 |